Matches in Nanopublications for { ?s ?p "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP654365.RAD3w7jr1dLa7krMVKrjFAg9J_JoPqylQHR8TjLxe0ANo130_assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP654365.RAD3w7jr1dLa7krMVKrjFAg9J_JoPqylQHR8TjLxe0ANo130_provenance.
- assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP789570.RAwackV4jmA0bWbBMgbi-0p-gwxJxNtaq3-9EnLNC1bjw130_assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789570.RAwackV4jmA0bWbBMgbi-0p-gwxJxNtaq3-9EnLNC1bjw130_provenance.
- assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1353850.RAThcIqZTFIME4laPrru-QL0q2n6hq7FXYPVFHSLXDv8o130_assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1353850.RAThcIqZTFIME4laPrru-QL0q2n6hq7FXYPVFHSLXDv8o130_provenance.
- NP1353853.RAcjbsnz5iL458Sf0WL_uX0wfF8m0BH6jspEuFrENEEZI130_assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1353853.RAcjbsnz5iL458Sf0WL_uX0wfF8m0BH6jspEuFrENEEZI130_provenance.
- NP611507.RAoj1kMnF64G57DExUU0s3TlnztvD-SljtMnkGI1MLx98130_assertion description "[To evaluate the expression of bcl-2 in transitional cell carcinoma (TCC) of the bladder; to compare bcl-2 expression with clinicopathological findings, p53 immunoreactivity, proliferating cell nuclear antigen (PCNA) expression, 2c deviation index (2cDI), 5c exceeding rate (5cER), and the mean nuclear area (MNA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP611507.RAoj1kMnF64G57DExUU0s3TlnztvD-SljtMnkGI1MLx98130_provenance.